Technical Analysis for ARNA - Arena Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 47.29 4.88% 2.20
ARNA closed up 2.5 percent on Friday, April 3, 2020, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Up
Historical ARNA trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 4.88%
Stochastic Reached Overbought Strength 4.88%
Overbought Stochastic Strength 4.88%
Crossed Above 20 DMA Bullish 7.50%
Fell Below 20 DMA Bearish 16.05%
Multiple of Ten Bullish Other 16.05%
Wide Bands Range Expansion 16.05%
Down 3 Days in a Row Weakness 16.05%
20 DMA Support Bullish 12.60%
Wide Bands Range Expansion 12.60%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Arena Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company offers BELVIQ, a drug candidate approved by the United States food and drug administration for chronic weight management in adults. It is also involved in the development of APD811, an agonist of the prostacyclin receptor, which is in Phase I clinical trials for the treatment of pulmonary arterial hypertension; and temanogrel, an inverse agonist of the serotonin 2A receptor that is in Phase I clinical trials for the treatment of thrombotic diseases. In addition, the company's preclinical development products comprise APD334, an agonist of the S1P1 receptor intended for the treatment of autoimmune diseases; APD371, an agonist of the cannabinoid receptor 2 intended for the treatment of pain; and GPR119 agonists intended for the treatment of type 2 diabetes. Further, it manufactures drug products under a manufacturing services agreement. The company has a marketing and supply agreement with Ildong Pharmaceutical Co., Ltd. for the commercialization of BELVIQ in South Korea. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.
Chemistry Health Biopharmaceutical Food Pain Diabetes Medication Autoimmune Diseases Pharmacology Pulmonary Arterial Hypertension Metabolic Diseases Treatment Of Autoimmune Diseases Inflammatory Cannabinoids United States Food And Drug Administration Chronic Weight Management Drug Products Manufacturing Services Agreement

Is ARNA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 64.48
52 Week Low 32.95
Average Volume 674,804
200-Day Moving Average 49.97
50-Day Moving Average 45.73
20-Day Moving Average 41.07
10-Day Moving Average 42.49
Average True Range 3.53
ADX 26.72
+DI 16.00
-DI 19.73
Chandelier Exit (Long, 3 ATRs ) 40.08
Chandelier Exit (Short, 3 ATRs ) 43.55
Upper Bollinger Band 46.34
Lower Bollinger Band 35.80
Percent B (%b) 0.88
BandWidth 25.68
MACD Line -0.62
MACD Signal Line -1.35
MACD Histogram 0.7349
Fundamentals Value
Market Cap 1.77 Billion
Num Shares 39.2 Million
EPS -0.74
Price-to-Earnings (P/E) Ratio -60.93
Price-to-Sales 8.96
Price-to-Book 12.74
PEG Ratio 0.45
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 48.08
Resistance 3 (R3) 47.86 46.65 47.58
Resistance 2 (R2) 46.65 45.89 46.76 47.41
Resistance 1 (R1) 45.87 45.42 46.26 46.09 47.25
Pivot Point 44.66 44.66 44.86 44.77 44.66
Support 1 (S1) 43.88 43.90 44.27 44.10 42.93
Support 2 (S2) 42.67 43.43 42.78 42.77
Support 3 (S3) 41.89 42.67 42.60
Support 4 (S4) 42.11